Haisco Pharmaceutical Group Co., Ltd.

Shenzhen Stock Exchange 002653.SZ

Haisco Pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: 6.70%

Haisco Pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) is 6.70% for the year ending December 31, 2023, a -32.83% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Haisco Pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 9.97%, a -35.34% change year over year.
Haisco Pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 15.42%, a -32.07% change year over year.
Haisco Pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 22.70%, a -3.04% change year over year.
Haisco Pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 23.41%, a 52.76% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Shenzhen Stock Exchange: 002653.SZ

Haisco Pharmaceutical Group Co., Ltd.

CEO	Ms. Xiu Lian Fan
IPO Date	Jan. 17, 2012
Location	China
Headquarters	No.17, Sanxiang Avenue
Employees	5,448
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Drugstores & Retail Pharmacies Personal Care Pet Food

Description

Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. The company offers small-volume injections, freeze-dried powder injections, powder injections, large-volume injections, active pharmaceutical ingredient, etc. for various therapeutic fields, including anti-infective, digestive system, blood system, nervous system, parenteral nutrition, antibiotics, first aid, anesthetics, and tumor; and tablets, capsules, granules, and ointments in the fields of cardiovascular, anti-infection, digestive system, CNS system, diabetes, and hepatic diseases. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Shannan, China.

Key trends

Past 5 years